Advanced-Stage Primary Cutaneous T-Cell Lymphoma Treated with Bexarotene and Denileukin Diftitox

被引：1

作者：

Cervigon-Gonzalez, Ivn ^{[1
]}

Torres-Iglesias, Luis Miguel ^{[1
]}

Palomo-Arellano, Angel ^{[1
]}

Gil-Pascual, Braulio ^{[1
]}

机构：

[1] Hosp Nuestra Senora Prado, Dermatol & Anat Pathol Unit, Talavera Reina, Spain

来源：

CASE REPORTS IN DERMATOLOGY | 2011年 / 3卷 / 01期

关键词：

Cutaneous T-cell lymphoma; Mycosis fungoides; Bexarotene; Denileukin diftitox;

D O I：

10.1159/000324185

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Advanced-stage primary cutaneous T-cell lymphoma has an unfavorable prognosis and low survival rates. Aggressive treatment with chemotherapy is not curative and causes considerable side effects. The combination of bexarotene and denileukin diftitox is associated with an acceptable safety profile and a likely synergistic effect because bexarotene is capable of modulating expression of IL-2 receptor and enhance the susceptibility of T-cell leukemia cells to denileukin diftitox. In the case reported here, the response to this combined treatment was satisfactory and well tolerated. The patient showed a complete regression of pruritus, restlessness, and insomnia. Skin lesions improved partially, and lymphadenopathy was reduced and finally disappeared completely.

引用

页码：13 / 17

页数：5

共 15 条

[1]

Assaf C, 2008, DERMATOL CLIN, V26, P21

[2] INTERLEUKIN-2 RECEPTOR TARGETED CYTO-TOXICITY INTERLEUKIN-2 RECEPTOR MEDIATED ACTION OF A DIPHTHERIA-TOXIN RELATED INTERLEUKIN-2 FUSION PROTEIN [J].

BACHA, P ;

WILLIAMS, DP ;

WATERS, C ;

WILLIAMS, JM ;

MURPHY, JR ;

STROM, TB .

JOURNAL OF EXPERIMENTAL MEDICINE, 1988, 167 (02) :612-622

[3] Biologic correlates of response and survival in patients with cutaneous T-cell lymphoma treated with denileukin diftitox [J].

Chin, Kevin M. ;

Foss, Fraricine M. .

CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (03) :199-204

[4]

DiVenuti GM, 2001, BLOOD, V98, p601A

[5] Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results [J].

Duvic, M ;

Hymes, K ;

Heald, P ;

Breneman, D ;

Martin, AG ;

Myskowski, P ;

Crowley, C ;

Yocum, RC .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (09) :2456-2471

[6]

Duvic M, 2001, ARCH DERMATOL, V137, P581

[7] A phase-1 trial of bexarotene and denileukin difftitox in patients with relapsed or refractory cutaneous T-cell lymphoma [J].

Foss, F ;

Demierre, MF ;

DiVenuti, G .

BLOOD, 2005, 106 (02) :454-457

[8]

Foss F M, 2001, Clin Lymphoma, V1, P298, DOI 10.3816/CLM.2001.n.005

[9] Efficacy of denileukin diftitox in subcutaneous panniculitis-like T-Cell lymphonia [J].

Hathaway, Tanya ;

Subtil, Antonio ;

Kuo, Philip ;

Foss, Francine .

CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (08) :541-545

[10] Regression of extranodal natural killer/T-cell lymphoma, nasal type with denileukin diftitox (Ontak®) and bexarotene (Targretin®):: report of a case [J].

Kerl, K ;

Prins, C ;

Cerroni, L ;

French, LE .

BRITISH JOURNAL OF DERMATOLOGY, 2006, 154 (05) :988-991

← 1 2 →